ライフサイエンスコーパス: natriuretic peptide

1 in T) and dysfunction (N-terminal pro-B-type natriuretic peptide).

2 ate) on binding of ANP, BNP (atrial or brain natriuretic peptide).

3 tocrit, and NT-proBNP (N-terminal pro b-type natriuretic peptide).

4 of-life, and NT-proBNP (N-terminal pro-brain natriuretic peptide).

5 biomarkers (including N-terminal pro-B-type natriuretic peptide).

6 -dependent degradation of vasodilator atrial natriuretic peptide.

7 l strain, and N-terminal prohormone of brain natriuretic peptide.

8 grades vasoactive peptides, including atrial natriuretic peptide.

9 ic variables including N-terminal pro-B-type natriuretic peptide.

10 ype natriuretic peptide (BNP) and the C-type natriuretic peptide.

11 ejection fraction and N-terminal pro-B-type natriuretic peptide.

12 itional markers, such as N-terminal probrain natriuretic peptide.

13 nt, peripheral ischemic preconditioning, and natriuretic peptide.

14 x turnover), ST-2, and N-terminal pro-B-type natriuretic peptide.

15 ardiac troponin T, and N-terminal pro-B-type natriuretic peptide.

16 ith the cardiac marker N-terminal pro-B-type natriuretic peptide.

17 tion rate >=30 mL/min/1.73m(2), and elevated natriuretic peptides.

18 systolic function and remodeling and reduces natriuretic peptides.

19 riable changes in concentrations of multiple natriuretic peptides.

20 improvements in HF-related health status or natriuretic peptides.

21 (including NT-proBNP [N-terminal pro-B-type natriuretic peptide]).

22 , medical therapy escalation, and BNP [brain natriuretic peptide]).

23 -197) ng/L, NT-proBNP (N-terminal-pro-B-type natriuretic peptide) 624 (307-1312) ng/L, hs-cTnI (high

24 n (83.0 vs. 28.5 ng/L; P < 0.05), and B-type natriuretic peptide (7,424.5 vs. 3,209.5 pg/mL; P < 0.05

25 t AF-associated human variant p.Ile138Thr in natriuretic peptide A (NPPA) encoding the atrial natriur

26 he NT-proBNP (N-terminal prohormone of brain natriuretic peptide)-a biomarker that is used for screen

27 s pro-atrial natriuretic peptide into atrial natriuretic peptide, a cardiac hormone that regulates bl

28 Npr2 abolished protective effects of C-type natriuretic peptide, a ligand for Npr2, against death of

29 Vosoritide is a biologic analogue of C-type natriuretic peptide, a potent stimulator of endochondral

30 Also central to diagnosis are elevated natriuretic peptides above age- and context-specific thr

31 Plasma aldosterone, B-type natriuretic peptide, active renin concentration, and cli

32 lar markers, including Nppb, encoding B-type natriuretic peptide, after infarction.

33 ocalin) and NT-proBNP (N-terminal pro-B-type natriuretic peptide; all P<0.001).

34 NT-proBNP (N-terminal pro-B-type natriuretic peptide) alone at a cutoff of >800 identifie

35 Preoperative N-terminal pro-B-type natriuretic peptide and cardiovascular events after nonc

36 signaling by extracellular peptides (C-type natriuretic peptide and EGF receptor ligands) maintain t

37 impairment, and higher N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T conc

38 obustly associated with N-terminal pro-brain natriuretic peptide and incident HF or death.

39 key zinc-dependent metallopeptidases in the natriuretic peptide and kinin systems and renin-angioten

40 To further investigate the local action of natriuretic peptide and p38 MAPK in podocytes, we genera

41 size) with concomitant N-terminal pro-brain natriuretic peptide and subsequent HF hospitalization or

42 biomarkers of post-MI HF: N-terminal B-type natriuretic peptide and troponin T, and newly emergent b

43 l capacity, biomarkers (N-terminal pro-brain natriuretic peptide and/or high-sensitivity troponin T),

44 the prognostic value of sST2 is additive to natriuretic peptides and (in the case of chronic HF) to

45 Changes in insulin signaling, circulating natriuretic peptides and adipokines, and varied expressi

46 Some ubiquitous biomarkers, for example, natriuretic peptides and cardiac troponin, may assist in

47 e regulation, indicated by the expression of natriuretic peptides and proteins related to the renin-a

48 oming the resistance to diuretics and atrial-natriuretic-peptide and inhibiting Na-H exchangers and s

49 re (1) mean NT-proBNP (N-terminal pro b-type natriuretic peptide) and (2) proportion of patients with

50 ANP (atrial natriuretic peptide) and BNP (B-type natriuretic peptide

51 of cardiac biomarkers (troponins and B-type natriuretic peptide) and cardiac dysfunction for 24-48 h

52 contrast to NT-proBNP (N-terminal pro-B-type natriuretic peptide) and hs-TnT (high-sensitivity tropon

53 NT-proBNP (N-terminal pro-brain-type natriuretic peptide) and myocardial perfusion reserve we

54 Both BNP (B-type natriuretic peptide) and NT-proBNP (N-terminal pro B-typ

55 natriuretic peptides (N-terminal pro-B type natriuretic peptide) and rest/exercise echocardiography

56 atrial natriuretic peptide), BNP (brain-type natriuretic peptide), and cGMP, and decreased plasma end

57 ial volume, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and fibrosis biomarkers; and lower

58 onin T (hsTnT), NT-proBNP (N-terminal B-type natriuretic peptide), and growth differentiation factor-

59 dinal strain, N-terminal prohormone of brain natriuretic peptide, and adverse cardiac outcomes compar

60 ve Risk Evaluation II, N-terminal pro-B-type natriuretic peptide, and cardiac troponin T concentratio

61 sma norepinephrine and N-terminal pro-B-type natriuretic peptide, and chemosensitivity to hypercapnia

62 , randomized treatment, N-terminal pro-brain natriuretic peptide, and clinical risk factors.

63 y greater reduction in N-terminal pro-B-type natriuretic peptide, and improved clinical outcomes comp

64 iltration rate, higher N-terminal pro-B-type natriuretic peptide, and lower peak Vo(2).

65 rular filtration rate, N-terminal pro-B-type natriuretic peptide, and peak oxygen consumption (Vo(2))

66 duced fat oxidation to affect cardiac atrial natriuretic peptide, and thus, induce adipose lipolysis,

67 otein, lipoprotein(a), N-terminal pro-B-type natriuretic peptide, and transferrin), and apolipoprotei

68 ndent prognostic value even beyond symptoms, natriuretic peptides, and Meta-Analysis Global Group in

69 ed to as atrial natriuretic factor or atrial natriuretic peptide (ANP) and brain or B-type natriureti

70 iuretic peptide A (NPPA) encoding the atrial natriuretic peptide (ANP) causes inflammation, fibroblas

71 Effects of sacubitril/valsartan on atrial natriuretic peptide (ANP) concentrations in patients are

72 Atrial natriuretic peptide (ANP) influences glucose homeostasis

73 Atrial natriuretic peptide (ANP) is a peptide hormone that in r

74 Although atrial natriuretic peptide (ANP) is not amidated, Pam expressio

75 in the receptor-binding region of the A-type natriuretic peptide (ANP), demonstrating that they affec

76 Although neither atrial nor brain natriuretic peptide (ANP, BNP) is amidated, the major me

77 sin II (ANG II; vasoconstrictive) and atrial natriuretic peptide (ANP; vasodilatory) antagonize the b

78 Natriuretic peptides are substrates of neprilysin; hence

79 eptide) and NT-proBNP (N-terminal pro B-type natriuretic peptide) are widely used to aid diagnosis, a

80 NPs (natriuretic peptides) are cardiac-derived hormones that

81 ies study heart failure risk score excluding natriuretic peptides as the base model to which we added

82 igated the potential of uCNP (urinary C-type natriuretic peptide) as a biomarker for AKI.

83 cubitril/valsartan on results from different natriuretic peptide assays.

84 (28-scanning point method), and BNP (B-type natriuretic peptide) assessment during supine exercise e

85 de concentrations and compared the impact of natriuretic peptide-associated genetic variants on blood

86 ent effect on N-terminal prohormone of brain natriuretic peptide at 18 months was observed in the ove

87 siran lowered N-terminal prohormone of brain natriuretic peptide at 9 and 18 months (at 18 months, ra

88 ponin-T and NT-proBNP [N-terminal Pro-B-type natriuretic peptide]) at baseline (pre-ERT) and 12 month

89 associated with HF more closely than B-type natriuretic peptide (AUC = 0.97 versus 0.84, p = 0.011).

90 mRNA expression of myosin heavy chain 7 and natriuretic peptide B is up-regulated in both ventricles

91 ng, a 6-minute walk test, and measurement of natriuretic peptides before and 1 year after AVR.

92 e determined whether plasma levels of B-type natriuretic peptide (BNP) and cardiac troponin I are ass

93 (NP) family, which also includes the B-type natriuretic peptide (BNP) and the C-type natriuretic pep

94 With sacubitril/valsartan treatment, B-type natriuretic peptide (BNP) concentrations increase; it re

95 are substrates of neprilysin; hence, B-type natriuretic peptide (BNP) concentrations rise with nepri

96 at risk" for HFpEF given elevated brain-type natriuretic peptide (BNP) level; 160 had HFpEF by docume

97 class (HR 1.50; 95% CI 1.02-2.2), log brain natriuretic peptide (BNP) levels (HR 1.45; 95% CI 1.15-1

98 iac volume loading and increased serum brain natriuretic peptide (BNP) levels.

99 nnervated by pruritoceptors expressing brain natriuretic peptide (BNP) most of them contained mRNA fo

100 43 ms; P = 0.05), an elevated pre-TIPS brain natriuretic peptide (BNP) or N-terminal pro-brain natriu

101 t to derive a new staging system using brain natriuretic peptide (BNP) that would correlate with the

102 Brain natriuretic peptide (BNP) treatment increases heart func

103 ith an established biomarker for CVD, B-type Natriuretic Peptide (BNP), and echocardiographic paramet

104 Circulating RBP4, TTR, B-type natriuretic peptide (BNP), and troponin I (TnI) concentr

105 The utility of B-type Natriuretic Peptide (BNP), N-terminal proBNP (NT-proBNP)

106 atriuretic peptide (ANP) and brain or B-type natriuretic peptide (BNP), thereby demonstrating an endo

107 divided into a labeled data set (with B-type natriuretic peptide [BNP] result as a marker of CHF) and

108 ckness, increased lung levels of ANP (atrial natriuretic peptide), BNP (brain-type natriuretic peptid

109 icular ejection fraction <=40%, and elevated natriuretic peptides: BNP >=150 pg/mL or NT-proBNP >=600

110 (P=0.0042) and reduced N-terminal pro-B-type natriuretic peptide by 28% (2%-47%), P=0.038.

111 e levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) by 36% (32 800 +/- 24 300 ng/L to 2

112 reatine kinase, myoglobin, N-terminal B-type natriuretic peptide, C-reactive protein, and leukocyte c

113 changes in NT-proBNP (N-terminal pro-B-type natriuretic peptide), cardiac reverse remodeling, and he

114 Biomarker measurements included natriuretic peptides, cardiac troponins, plasminogen act

115 C-type natriuretic peptide (CNP) is a fundamental endothelial s

116 ro-BNP (NT-proBNP), proBNP(1-108), or C-type natriuretic peptide (CNP) is not well understood.

117 sus 40), higher median N-terminal pro-B-type natriuretic peptide concentration (403 versus 320 pg/mL;

118 acellular fluid volume, and in plasma B-type natriuretic peptide concentration (ratio of intervention

119 e effects of genetic variants on circulating natriuretic peptide concentrations and compared the impa

120 in 6 min, and N-terminal prohormone of brain natriuretic peptide concentrations between the 2 groups.

121 ese findings are important for comparison of natriuretic peptide concentrations in heart failure and

122 of a nonhypotensive pGC-A activator/designer natriuretic peptide, CRRL269, in a short-term, large ani

123 ss and log-transformed N-terminal brain-type natriuretic peptide), cTSD was predictive of preclinical

124 Short-term mechanical circulatory support, natriuretic peptide decile, glomerular filtration rate,

125 Plasma concentrations of natriuretic peptides decline with obesity in patients wi

126 N-terminal pro-B-type natriuretic peptide declined significantly in all 4 subg

127 Natriuretic peptides decrease RV afterload by promoting

128 inical information (eg, N terminal pro-brain natriuretic peptide, distinctive chest x-ray findings, a

129 the relationship between cardiac troponins, natriuretic peptides, ECV and their associations with in

130 er adjustment for age, N-terminal pro-B-type natriuretic peptide, ejection fraction, E/E', and left v

131 baseline to week 12 in N-terminal pro-B-type natriuretic peptide, ejection fraction, global longitudi

132 (atrial natriuretic peptide) and BNP (B-type natriuretic peptide), encoded by the clustered genes Npp

133 with reduced ejection fraction and elevated natriuretic peptides enrolled in the COSMIC-HF trial (Ch

134 without hospitalization), and with elevated natriuretic peptides, enrolled at 167 sites in 21 countr

135 F proteins (NT-proBNP [N-terminal pro-B type natriuretic peptide], ESM [endothelial cell-specific mol

136 rotein kinase IIdelta phosphorylation, brain natriuretic peptide expression, and sustained capillariz

137 antly raised levels of N-terminal pro B-type natriuretic peptide, ferritin, D-dimers, and cardiac tro

138 Exercise testing, echocardiography, B-type natriuretic peptide, functional health assessment, and m

139 ensitivity troponin T, N-terminal pro-B-type natriuretic peptide, growth-differentiation factor-15, a

140 N-terminal prohormone of brain natriuretic peptide >8500 ng/L could not be overcome for

141 ed cardiac biomarkers (N-terminal pro-B-type natriuretic peptide [>40 pg/mL] or troponin T [>0.6 pg/m

142 core >2, or NT-proBNP (N-terminal pro-B-type natriuretic peptide) >=40 pmol/L and among participants

143 The concept of natriuretic peptide guidance has been extensively studie

144 Assessment of BNP (B-type natriuretic peptide) has also been suggested by the Amer

145 Measures of serum cardiac troponins and natriuretic peptides have become established as prognost

146 BACKGROUND AND Natriuretic peptides have led the way as a diagnostic an

147 Natriuretic peptides have many physiological actions and

148 Plasma levels of natriuretic peptides have proven to be powerful diagnost

149 ional risk factors and N-terminal pro-B-type natriuretic peptide (hazard ratio per SD increment: 1.35

150 left atrium dimension, E/e', and pro B-type natriuretic peptide (hazard ratio, 1.05; 95% confidence

151 -1.39]) and NT-proBNP (N-terminal pro-B-type natriuretic peptide; hazard ratio, 1.73 [95% CI, 1.52-1.

152 e protein), NT-proBNP (N-terminal pro-B-type natriuretic peptide), HbA1C (glycated hemoglobin), and s

153 on, Galectin-3 (Gal-3), N-terminal proB-type natriuretic peptide, high sensitivity troponin T (hsTnT)

154 ronary artery calcium, N-terminal pro B-type natriuretic peptide, high-sensitivity cardiac troponin T

155 lso assayed NT-proBNP (N-terminal pro-B-type natriuretic peptide), hs-cTnT, CRP (C-reactive protein),

156 ion in inflammatory markers, D-dimer, B-type natriuretic peptide, IL-6, and IL-10 levels were common

157 When including B-type natriuretic peptide in the model, only a decreasing myoc

158 linical model improved modestly after adding natriuretic peptides in men (DeltaC-statistic = 0.006; l

159 55 +/- 10%; p < 0.001; n = 259), and B-type natriuretic peptide increased (median [interquartile ran

160 Importantly, proBNP (pro-brain natriuretic peptide) increased at 12 months in 20 millio

161 cystatin C, NT-proBNP (N-terminal pro-B-type natriuretic peptide), interleukin (IL)-6, and E-selectin

162 rritin, procalcitonin, N-terminal pro B-type natriuretic peptide, interleukin-6 level, and D-dimers.

163 d in cardiomyocytes that converts pro-atrial natriuretic peptide into atrial natriuretic peptide, a c

164 yocardial infarction, indicating that B-type natriuretic peptide is required to preserve postinfarct

165 of pharmacological agents that are based on natriuretic peptides is an area of active research, with

166 Background NT-proBNP (N-terminal pro-B-type natriuretic peptide) is useful in diagnosis and prognost

167 EF was 56%; and median N-terminal pro-brain natriuretic peptide level was 1403 pg/mL; 761 (96.5%) co

168 ents were women, median N-terminal pro-brain natriuretic peptide level was 918 pg/ml (interquartile r

169 iastolic diameter; serum troponin level; and natriuretic peptide level) in each individual.

170 Age, B-type natriuretic peptide level, renal dysfunction, 24-h AHI,

171 have evaluated adjusting HF therapy based on natriuretic peptide levels ("guided therapy") with incon

172 ile concurrently reducing circulating atrial natriuretic peptide levels (p < 0.01).

173 N-terminal pro-B-type natriuretic peptide levels decreased similarly in both g

174 roBNP levels of 1000 pg/mL or more or B-type natriuretic peptide levels of 250 pg/mL or more, regardl

175 N-Terminal pro-B type natriuretic peptide levels were below the level consider

176 ociation class II or III HFpEF with elevated natriuretic peptide levels were enrolled between May 10,

177 aride binding protein, troponin T, and brain natriuretic peptide levels were measured.

178 h HFrEF (ejection fraction </=40%), elevated natriuretic peptide levels within the prior 30 days, and

179 uality of life, higher N-terminal pro-B-type natriuretic peptide levels, and a poorer prognosis.

180 s feasibility, on-study retention, trends in natriuretic peptide levels, quality of life, and safety

181 0.0001), despite lower N-terminal pro-B-type natriuretic peptide levels.

182 NT-proBNP (N-terminal pro brain natriuretic peptide) levels are included in the multipar

183 ukin-6) and NT-proBNP (N terminal pro B-type natriuretic peptide) levels were examined in multivariab

184 n fraction, NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels, cardiac output/index, brach

185 <6 ng/L and NT-proBNP (N-terminal pro-B-type natriuretic peptide) <100 pg/mL), and those with ECG-LVH

186 3, NAC+NaHCO3, ischemic preconditioning, and natriuretic peptide may have nephroprotective effects, t

187 ncluding 4-dimensional flow, BNP (brain-type natriuretic peptide) measurement, functional capacity as

188 he reduced fat oxidation and elevated atrial natriuretic peptide message of cardiac hypertrophy.

189 iography, increased plasma concentrations of natriuretic peptides, mild-to-moderate renal insufficien

190 Current guidelines recommend use of natriuretic peptides (N-terminal pro-B type natriuretic

191 cardiomyocytes and CFs via the atrial/brain natriuretic peptide-natriuretic peptide receptor-1 pathw

192 ANP is a member of the natriuretic peptide (NP) family, which also includes the

193 Circulating natriuretic peptide (NP) levels are markedly lower in he

194 Phosphodiesterase-9 (PDE9) reduces natriuretic peptide (NP) signaling and may be involved i

195 thway, the evaluation of nitrates, synthetic natriuretic peptides (NP), and NP analogs has yielded mi

196 Natriuretic peptides (NPs) are hormones involved in main

197 Cardiac natriuretic peptides (NPs) play a fundamental role in ma

198 The cardiac natriuretic peptides (NPs), atrial NP and B-type NP, reg

199 ing coronary angiography, independent of the natriuretic peptide NT-proBNP, kidney function and of ma

200 alised, and who had an N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) concentration less than

201 tion (LVEF) >=55%, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) >=300 pg/ml.

202 ent staging systems use N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiac troponins T

203 awn for the biomarkers N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity car

204 N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity car

205 Serum N-terminal-pro-B-type natriuretic peptide (NT-proBNP) and total testosterone l

206 roponin T (hs-cTnT) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) are at high risk of infe

207 ce (6MWD) and change in N-terminal pro-brain natriuretic peptide (NT-proBNP) by after therapy.

208 g microRNA panels with N-terminal pro-B-type natriuretic peptide (NT-proBNP) clearly improved specifi

209 ortional change in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from basel

210 Increased N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration predicts p

211 wever, the role of amino-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations among PHI

212 tril-valsartan reduces N-terminal pro-b-type natriuretic peptide (NT-proBNP) concentrations.

213 s biosensors to measure N-terminal pro-brain natriuretic peptide (NT-proBNP) in human serum within it

214 Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) is considered a marker t

215 uretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-proBNP) level, an elevated E/A r

216 tone and usual care on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels compared with usu

217 walk distance, plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and health statu

218 phy, leading to elevated N-terminal probrain natriuretic peptide (NT-proBNP) levels.

219 -life (QOL) score, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels.

220 (GDMT) by reducing amino-terminal pro-B-type natriuretic peptide (NT-proBNP) was not superior to GDMT

221 c troponin T (hs-cTnT) and N-terminal B-type natriuretic peptide (NT-proBNP) were measured using seru

222 kers (such as N-terminal prohormone of brain natriuretic peptide (NT-proBNP)) and a measure of functi

223 troponin I (hs-cTnI), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high-sensitivity C-

224 eactive protein (CRP), N-terminal pro b-type natriuretic peptide (NT-proBNP), cardiac troponin I (cTn

225 ied the association of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitive troponin

226 ary biomarkers such as N-terminal pro B-type natriuretic peptide (NT-proBNP), urine output (UOP), and

227 e assessments included N-terminal pro-B-type natriuretic peptide (NT-proBNP).

228 y score (KCCQ-OSS) and N-terminal pro-B-type natriuretic peptide (NT-proBNP).

229 questioned, and use of N-terminal pro-B-type natriuretic peptides (NT-proBNP) has been preferred and

230 >=6 ng/L] and stress (N-terminal pro-B-type natriuretic peptide [NT-proBNP] >=100 pg/mL) can inform

231 tom classification, and N-terminal pro-brain natriuretic peptide [NT-proBNP] level) at 6 months, 20 e

232 nins I and T, N-terminal prohormone of brain natriuretic peptide [NT-proBNP]) to predict baseline sus

233 Elevated natriuretic peptides occurring mid-first cycle of treatm

234 ic HF, ejection fraction >=45%, and elevated natriuretic peptides or a prior HF hospitalization.

235 troponin I, NT-proBNP (N-terminal pro-B-type natriuretic peptide), or high-sensitivity C-reactive pro

236 augmentation index at 12 months, BP, B-type natriuretic peptide, or physical function.

237 l cyclase activity, increased sensitivity to natriuretic peptide, or reduced the Michaelis constant i

238 p = 0.003), and higher N-terminal pro-B-type natriuretic peptide (p = 0.02) than those with <=Mild TR

239 e (p < 0.0001) or clinical score plus B-type natriuretic peptide (p = 0.02).

240 exercise capacity, and N-terminal pro-brain natriuretic peptide (P>0.30 for all).

241 .03]), and markers of cardiac stretch (brain natriuretic peptide [P < .001] and N-terminal fragment o

242 N-terminal fragment of the prohormone brain natriuretic peptide [P = .001]) in HIV.

243 stance, and NT-proBNP (N-terminal pro-B-type natriuretic peptide; P<0.05 for all).

244 decrease in NT-proBNP (N-terminal pro-B-type natriuretic peptide; P=0.002), and lower levels of PRA (

245 Studies have reported that natriuretic peptides provide prognostic information for

246 or soluble ST2 and amino-terminal pro-B-type natriuretic peptide provides early risk assessment beyon

247 ; Meng test p = 0.03), N-terminal pro-B-type natriuretic peptide (r = 0.56 vs. r = 0.17; Meng test p

248 -type, endothelium-specific CNP(-/-), global natriuretic peptide receptor (NPR)-B(-/-) and NPR-C(-/-)

249 Human genetic variation in the NPR1 (natriuretic peptide receptor 1 gene, encoding NPR-A, atr

250 tide receptor 1 gene, encoding NPR-A, atrial natriuretic peptide receptor 1) was recently shown to af

251 Mutations in natriuretic peptide receptor 2 (Npr2) gene cause a rare

252 ferentiation via the guanylate cyclase NPR2 (natriuretic peptide receptor 2) and not the G-protein-co

253 e G-protein-coupled clearance receptor NPR3 (natriuretic peptide receptor 3).

254 the interaction between ANP and its receptor natriuretic peptide receptor A and reduces intracellular

255 cking gastrin-releasing peptide receptor and natriuretic peptide receptor A by genetic approaches or

256 ecifically for the interaction of human anti-natriuretic peptide receptor A IgG4 with the neonatal Fc

257 ncluding gastrin-releasing peptide receptor, natriuretic peptide receptor A, neuromedin B receptor, a

258 for IgG4 (S228P), an antibody targeting the natriuretic peptide receptor A, show a previously unreco

259 ANP acting through natriuretic peptide receptor-A (NPRA) lowers blood press

260 nction using Npr1 (encoding guanylyl cyclase/natriuretic peptide receptor-A, GC-A/NPRA) gene-knockout

261 e learned of the potential role of an NPR-C (natriuretic peptide receptor-C) in atrial fibrosis and t

262 ough specific NP receptors, including NPR-C (natriuretic peptide receptor-C), are cardioprotective ho

263 in myocytes, as it was distinct from atrial natriuretic peptide receptor-cGMP-PKG-RyR2 Ser-2808 sign

264 lated manner, two polypeptide hormones - the natriuretic peptides - referred to as atrial natriuretic

265 Natriuretic peptides regulate multiple physiologic syste

266 T (cTnT) and N-terminal prohormone of brain natriuretic peptide) related to hemodynamic activity.

267 as endothelin-1 caused itch-selective B-type natriuretic peptide release.

268 rdiomyocyte death, and N-terminal pro B-type natriuretic peptide release; all are classical hallmarks

269 Important clinical entities associated with natriuretic peptide research include heart failure, obes

270 n- beyond traditional risk factors including natriuretic peptides, risk scores, and symptoms-in heart

271 betes, renal function, N-terminal pro-b-type natriuretic peptide serum concentration, and right ventr

272 hy (MRN) with hsTNT and N-terminal pro-brain natriuretic peptide serum levels in patients with T2D.

273 G1 is a primary effector of nitric oxide and natriuretic peptide signalling, and protects against hea

274 These include natriuretic peptides, soluble suppressor of tumorgenicit

275 scovery of atrial secretory granules and the natriuretic peptides stored in them identified the atriu

276 ips between NT-proBNP (N-terminal Pro-B-type natriuretic peptide), systolic blood pressure, and diast

277 dyspnea, increased plasma concentrations of natriuretic peptides, systolic blood pressure of at leas

278 dy), high-sensitivity troponin I, and B-type natriuretic peptide ( Table 1 ).

279 g levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) than HF patients without AF.

280 d change in NT-proBNP [N-terminal pro-B-type natriuretic peptide]), there was a significant increase

281 yclase receptors that mediate the effects of natriuretic peptides through the generation of intracell

282 After adjusting for baseline natriuretic peptides, time-updated Meta-Analysis Global

283 circulating NT-proBNP (N-terminal pro-B-type natriuretic peptide), TNF-alpha, IL-6, IL-12, IL-17, mal

284 of soluble ST2 and amino-terminal pro-B-type natriuretic peptide to clinical parameters for risk stra

285 Atrial natriuretic peptide together with PDE9a inhibitor were a

286 ft ventricular ejection fraction, pro-B-type natriuretic peptide, troponin I, and C-reactive protein

287 higher risk: NT-proBNP [N-terminal proB-type natriuretic peptide], TSP2 [thrombospondin-2], MBL [mann

288 In primary human keratinocytes, B-type natriuretic peptide upregulated genes promoting dermatol

289 s were normal, whereas N-terminal pro B-type natriuretic peptide was 10 times the upper limit of norm

290 quartile range) concentration of BNP (B-type natriuretic peptide) was 124 (69-197) ng/L, NT-proBNP (N

291 Mean BNP (B-type natriuretic peptide) was elevated (5743 pg/mL).

292 NT-proBNP (N-terminal pro-B-type natriuretic peptide) was not affected.

293 Natriuretic peptides were highly predictive of CVAEs; ho

294 tients who fulfilled entry criteria for both natriuretic peptides were included in the present analys

295 levation of NT-proBNP (N-terminal pro-B-type natriuretic peptide) were eligible.

296 RI, and log NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) were retained (chi(2), 62.2; P<0.00

297 onal area, and the expression of ANP (atrial natriuretic peptide) were significantly attenuated in th

298 levation of NT-proBNP (N-terminal pro-B-type natriuretic peptide), were eligible.

299 NPs (natriuretic peptides), which elicit their effects throug

300 assessed the association of levels of these natriuretic peptides with the subsequent risk of cardiov